Is There a Role for Allogeneic Transplantation in Chronic Myeloid Leukemia?

Noam Benyamini; Jacob M Rowe


Expert Rev Hematol. 2013;6(6):759-765. 

In This Article

Five-year View

Even with the most optimistic predictions, TKIs will be able to provide cure to a very small proportion of patients only. There is no efficient and safe medical treatment for TKI intolerant and resistant patients. Moreover, finding a new treatment for advanced phases of CML, other than HSCT, is very problematic nowadays due to a very small patient population, which makes large prospective studies impossible and decreases motivation of pharmaceutical industry.

Despite continuously decreasing indications for HSCT in CML in the last few years, and the difficulty in identifying those in need for HSCT, there is no doubt that this treatment modality will still have an important role in the management of patients in the next few years.